At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug .
At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug .
Breaking: The US FDA Just Granted Priority Review Of An MDMA Treatment For PTSD menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for inflammatory skin conditions.
MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its Phase 2 MIRA trial evaluating the Nanobody sonelokimab in patients with moderate-to-severe